drugset / Trial / NCT01638715
A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find biological response patterns of patients with rheumatoid arthritis to drugs with different biologic modes of action. This study should help to predict therapeutic responses and to find the right therapy for the right patient.
Timeline
- Start
- 2012-05
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abatacept | Other / unclassified | 125 mg | Intravenous |
| Subject | Abatacept | Other / unclassified | 500 mg | Intravenous |
| Subject | Abatacept | Other / unclassified | 750 mg | Intravenous |
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 162 mg | Intravenous |